Prograf (Tacrolimus Granules for Suspension) and Valganciclovir Oral Solution
Determining the interaction of Prograf (Tacrolimus Granules for Suspension) and Valganciclovir Oral Solution and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using valGANciclovir together with tacrolimus. Combining these medications may increase the risk of kidney, nerve damage, and/or side effects that affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek medical attention if you experience signs and symptoms that may suggest kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Be sure to drink plenty of fluids if you develop diarrhea or vomiting during treatment with these medications, as dehydration can also harm the kidney. In addition, let your doctor know if you develop seizures; hearing problems; or numbness, burning or tingling in your hands and feet. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: The concurrent or sequential use of tacrolimus and ganciclovir may increase the risk of toxicities such as myelotoxicity, nephrotoxicity, and neurotoxicity. Patients who are debilitated, dehydrated, or who have preexisting renal dysfunction may be at a greater risk of developing adverse reactions.
MANAGEMENT: Some authorities advise that these medicines should be coadministered only if the benefits are anticipated to outweigh the potential risks. If concomitant use is required, close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) as well as for the development of severe hematologic adverse effects is recommended.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: tacrolimus
Brand name: Prograf, Astagraf XL, Envarsus XR, Hecoria
Synonyms: Prograf
Generic Name: valganciclovir
Brand name: Valcyte
Synonyms: Valganciclovir, ValGANciclovir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Prograf (Tacrolimus Granules for Suspension)-Valganciclovir Solution
- Prograf (Tacrolimus Granules for Suspension)-Valganciclovir Tablets
- Prograf (Tacrolimus Granules for Suspension)-Valisone
- Prograf (Tacrolimus Granules for Suspension)-Valium
- Prograf (Tacrolimus Granules for Suspension)-Valium injection
- Prograf (Tacrolimus Granules for Suspension)-Valproate
- Valganciclovir Oral Solution-Prograf (Tacrolimus Injection)
- Valganciclovir Oral Solution-Prograf Intravenous
- Valganciclovir Oral Solution-Prohance
- Valganciclovir Oral Solution-ProHance Injection
- Valganciclovir Oral Solution-Prohist LQ
- Valganciclovir Oral Solution-Prolensa